pindolol has been researched along with Leukemia P388 in 1 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Leukemia P388: An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Amico, C | 1 |
| Crescimanno, M | 1 |
| Armata, MG | 1 |
| Leonardi, V | 1 |
| Palazzoadriano, M | 1 |
| D'Alessandro, N | 1 |
1 other study available for pindolol and Leukemia P388
| Article | Year |
|---|---|
Number and functionality of beta-adrenergic receptors in the mouse lymphocytic P388 leukemia as a doxorubicin-sensitive and -resistant variant.
Topics: Adrenergic beta-Antagonists; Animals; Colforsin; Cyclic AMP; Doxorubicin; Drug Resistance; Leukemia | 1992 |